A roundup of upcoming FDA decisions for the fourth quarter of 2026 highlights potential inflection points for investors and clinicians. The brief points to anticipated decisions on a new cancer immunotherapy and medicines relevant to the longer-term pipelines of Roche, GSK, and Gilead. While specific compounds are not detailed in the excerpt, the structure signals the type of decisions market participants track: approvals or post-marketing determinations that can shift commercial expectations and development strategy across oncology. For biotech professionals, the practical takeaway is timing—preparing for regulatory outcomes that can affect trial designs, partnering discussions, and formulary planning. The roundup also emphasizes that multiple late-stage readouts are likely to land around the same period, concentrating attention on the next wave of FDA outputs.